15. November 2017
Taylor Wessing advised InflaRx GmbH on its Initial Public Offering (IPO) on the Nasdaq stock exchange in New York. In connection with the IPO, InflaRx GmbH has become a subsidiary of the newly incorporated InflaRx N.V. InflaRx N.V. has offered and fully placed new shares with proceeds from the issue of around 100 million US-$ in its public offer in the United States.
Shortly before the IPO and with the support of Taylor Wessing, InflaRx GmbH had carried out a financing round with a volume of around 25.5 million Euro with the participation of the well-known US financial investors RaCapital, Bain Capital and Cormorant Asset Management. At the same time, existing shares of InflaRx GmbH worth around EUR 21.3 million were successfully sold to new investors.
InflaRx focuses, in particular, on innovative therapeutic solutions for the treatment of inflammatory diseases.
Davis Polk & Wardwell and Nauta Dutilh advised InflaRx N.V. under U.S. and Dutch law.
“The outstanding legal advice and support of Taylor Wessing, NautaDutilh, and Davis Polk & Wardwell on our private placement of shares followed by the reorganisation with the subsequent U.S. IPO have made a significant contribution to the company’s success “, says Prof. Dr. med. Niels Riedemann (Founder and CEO of InflaRx).
J.P. Morgan, Leerink and BMO accompanied the transaction as underwriter being advised by Goodwin Procter.
Legal advisors to the company:
Taylor Wessing: Lead: Hassan Sohbi (Partner, Corporate / Venture Capital, Frankfurt) and Ulrich Reers (Partner, Corporate / Capital Markets, Frankfurt), Dr. Simon Weppner (Partner, Tax, Düsseldorf), Dr. Manja Epping (Partner, Pharma, Munich), Dr. Anja Lunze (Partner, IP, Munich), Dr. Jan Grawe (Salary Partner, Employment Law, Frankfurt), Olga Radjuk, Marvin Singh (both Corporate / Venture Capital), David Becker (M&A), Li Alena Backstein (Corporate / Capital Markets) (all Associates, Frankfurt), Stefanie Morgenstern (Associate, Tax, Dusseldorf)